New drug tested for rare, painful inflammatory disease
NCT ID NCT02648581
Summary
This small, early-stage study tested whether a drug called ustekinumab could help control symptoms of Behçet disease, a rare inflammatory condition. It involved 16 adults with active disease, specifically targeting painful mouth sores or serious eye inflammation. The goal was to see if this biologic drug, which blocks specific immune system proteins, could reduce these symptoms over 24 weeks.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BEHÇET DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hôpital Cochin, Department of Internal Medicine, National Reference Center for Autoimmune and Systemic Diseases
Paris, Paris, 75014, France
Conditions
Explore the condition pages connected to this study.